Replies to post #4351 on Ariad Pharmaceuticals Inc fka ARIA

[vidpok45]

one can only hope that with the optimized population of patients that phase 3 will have more robust results than phase 2, but I am very doubtful.

[poorgradstudent]

mTor:

Actually, what I'm finding out is that mTor is a pretty useful overall target to mediate cell growth mechanisms. We're using it in post-heart transplant patients and have tried it in a couple of preclinical heart failure models and there is a clear benefit.

I think the question mark regarding rida use in oncology is whether it is mTORC1 or 2 that is mediating the growth effect in the specific indication, and how well rida does blocking 2 in addition to 1.